Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2747)
All Articles published online
|
Aug 14, 2007 (publication date) through Apr 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090 [PMID: 17696226 DOI: 10.3748/wjg.v13.i30.4085] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i30/4085.htm |
| Number | Citing Articles |
| 1 |
Hie-Won Hann, Vicki L. Gregory, Jonathan S. Dixon, Keith F. Barker. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B. Hepatology International 2008; 2(4): 440 doi: 10.1007/s12072-008-9105-y
|
| 2 |
Man-Fung Yuen, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai. Prevention and management of drug resistance for antihepatitis B treatment. The Lancet Infectious Diseases 2009; 9(4): 256 doi: 10.1016/S1473-3099(09)70056-8
|
| 3 |
Erica Villa, Barbara Lei, Gloria Taliani, Amalia Graziosi, Rosina Critelli, Monica Luongo, William Gennari, Marcello Bianchini, Ilva Ferretti. Pretreatment with Pegylated Interferon Prevents Emergence of Lamivudine Mutants in Lamivudine-Naive Patients: A Pilot Study. Antiviral Therapy 2009; 14(8): 1081 doi: 10.3851/IMP1465
|
| 4 |
Juan Wang, Ling-yao Du, Xia Zhu, En-qiang Chen, Hong Tang. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Indian Journal of Medical Microbiology 2015; 33: S20 doi: 10.4103/0255-0857.148827
|
| 5 |
Hyung Joon Yim, Seong Gyu Hwang. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clinical and Molecular Hepatology 2013; 19(3): 195 doi: 10.3350/cmh.2013.19.3.195
|
| 6 |
Shahinul Alam, Golam Azam, Golam Mustafa, Nooruddin Ahmad, Belalul Islam, Provat Kumar Podder, Mobin Khan. Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis B. Hepatology International 2008; 2(4): 494 doi: 10.1007/s12072-008-9095-9
|
| 7 |
Hae Rim Kim, Seong Hee Kang, Hyung Joon Yim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Kwan Soo Byun. Need of Treatment Modification During Entecavir Therapy in Patients with Chronic Hepatitis B: Long-Term Follow-Up Results for 120 Months. Microorganisms 2025; 13(2): 218 doi: 10.3390/microorganisms13020218
|
| 8 |
Jesse Civan, Hie Won Hann. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?. Expert Opinion on Drug Safety 2015; 14(6): 865 doi: 10.1517/14740338.2015.1032243
|
| 9 |
Rui Yu, Rong Fan, Jinlin Hou. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Frontiers of Medicine 2014; 8(2): 135 doi: 10.1007/s11684-014-0331-5
|
| 10 |
Nicholas Noverati, Vivian Yan, Jay W. Jun, Dina Halegoua-DeMarzio, Hie-Won Hann. The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time. Livers 2023; 3(3): 325 doi: 10.3390/livers3030024
|
| 11 |
Ki Bae Bang, Hong Joo Kim. Management of antiviral drug resistance in chronic hepatitis B. World Journal of Gastroenterology 2014; 20(33): 11641-11649 doi: 10.3748/wjg.v20.i33.11641
|
| 12 |
Lanish Singh, Trevor Graham Bell, Mukhlid Yousif, Anna Kramvis. Response of hepatitis B virus to antiretroviral treatment containing lamivudine in HBsAg‐positive and HBsAg‐negative HIV‐positive South African adults. Journal of Medical Virology 2019; 91(5): 758 doi: 10.1002/jmv.25375
|
| 13 |
Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li. Current status of drug therapy for chronic hepatitis B. World Journal of Gastroenterology 2025; 31(2): 99443 doi: 10.3748/wjg.v31.i2.99443
|
| 14 |
Guvenc Kockaya, Akin Kose, Fatma Betul Yenilmez, Oktay Ozdemir, Ece Kucuksayrac. Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. Cost Effectiveness and Resource Allocation 2015; 13(1) doi: 10.1186/s12962-015-0046-8
|
| 15 |
Xue-Jie Wu, Yan Wang, Ji Chen, Gui-Qiang Wang. Baseline predictors of virological response for chronic hepatitis B patients. World Journal of Gastroenterology 2009; 15(34): 4311-4315 doi: 10.3748/wjg.15.4311
|
| 16 |
Julien Lupo, Sylvie Larrat, Marie-Noëlle Hilleret, Raphaële Germi, Véronique Boyer, Sandrine Nicod, Gérard Barguès, Vincent Leroy, Jean-Marie Seigneurin, Jean-Pierre Zarski, Patrice Morand. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. Journal of Virological Methods 2009; 156(1-2): 52 doi: 10.1016/j.jviromet.2008.10.028
|
| 17 |
Jörg Petersen, Maria Buti. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Review of Gastroenterology & Hepatology 2012; 6(6): 683 doi: 10.1586/egh.12.52
|